Novartis : Phase III Trial Results Show Sustained Efficacy & Long-term Safety Of Fabhalta In PNH
11/12 04:35
(RTTNews) - Novartis (NVS) said it will present new 48-week results from Phase III APPLY-PNH trial of Fabhalta (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria at the 65th American Society of Hematology Annual Meeting & Exposition or ASH....